RD-RAP: beyond rare disease patient registries, devising a comprehensive data and analytic framework

Within the 21 APEC economies alone, there are an estimated 200 million individuals living with a rare disease. As such, health data on these individuals, and hence patient registries, are vital. However, registries can come in many different forms and operating models in different jurisdictions. They possess a varying degree of functionality and are used for a variety of purposes. For instance registries can facilitate service planning as well as underpin public health and clinical research by providing de-identified data to researchers. Furthermore, registries may be used to create and disseminate new knowledge to inform clinical best practice and care, to identify and enrol participants for clinical trials, and to enable seamless integration of patient data for diagnostic testing and cascade screening. Registries that add capability such as capturing patient reported outcomes enable patients, and their carers, to become active partners in their care, rapidly furthering research and ensuring up-to-date practice-based evidence. Typically, a patient registry centres around the notion of health data ‘capture’, usually for only one or a small subset of the functions outlined above, thereby creating fragmented datasets that, despite the best efforts and intentions, make it difficult to exchange the right data for the right purpose to the right stakeholder under appropriate governance arrangements. Trying to incorporate maximum functionality into a registry is an obvious strategy, but monolithic software solutions are not desirable. As an alternative, we propose that it is important to incorporate analytics as core to a patient registry, rather than just utilising registries as a ‘data capture’ solution. We contend that embracing an analytics-centric focus makes it reasonable to imagine a future where it will be possible to evaluate the individual outcomes of health interventions in real time. The purposeful and, importantly, the repurposable application of health data will allow stakeholders to extract, create and reuse knowledge to improve health outcomes, assist clinical decision making, and improve health service design and delivery. To realise this vision, we introduce and describe the concept of a Rare Disease Registry and Analytics Platform (RD-RAP); one that we hope will make a meaningful difference to the lives of those living with a rare disease.

[1]  A. Slade,et al.  Patient reported outcome measures in rare diseases: a narrative review , 2018, Orphanet Journal of Rare Diseases.

[2]  P. Clifton,et al.  Design of the Familial Hypercholesterolaemia Australasia Network Registry: Creating Opportunities for Greater International Collaboration , 2017, Journal of atherosclerosis and thrombosis.

[3]  M. Bellgard,et al.  Research protocol: The initiation, design and establishment of the Global Angelman Syndrome Registry , 2018, Journal of intellectual disability research : JIDR.

[4]  N. Zeps,et al.  Design of a framework for the deployment of collaborative independent rare disease-centric registries: Gaucher disease registry model , 2018, Blood cells, molecules & diseases.

[5]  Christophe Béroud,et al.  Dispelling myths about rare disease registry system development , 2013, Source Code for Biology and Medicine.

[6]  Finding Benefit in n-of-1 Trials. , 2019, JAMA internal medicine.

[7]  Christopher H Schmid,et al.  Individual (N-of-1) trials can be combined to give population comparative treatment effect estimates: methodologic considerations. , 2010, Journal of clinical epidemiology.

[8]  F. Bianchi,et al.  Recommendations for Improving the Quality of Rare Disease Registries , 2018, International journal of environmental research and public health.

[9]  M. Bellgard,et al.  The role of patient registries for rare genetic lipid disorders , 2018, Current opinion in lipidology.

[10]  Matthew I. Bellgard,et al.  Rare Disease Research Roadmap: Navigating the bioinformatics and translational challenges for improved patient health outcomes , 2014 .

[11]  Christopher H. Schmid,et al.  Single-patient (n-of-1) trials: a pragmatic clinical decision methodology for patient-centered comparative effectiveness research. , 2013, Journal of clinical epidemiology.

[12]  S. Cano,et al.  Measuring what matters to rare disease patients – reflections on the work by the IRDiRC taskforce on patient-centered outcome measures , 2017, Orphanet Journal of Rare Diseases.

[13]  N. Dreyer,et al.  Registries for Evaluating Patient Outcomes: A User’s Guide , 2010 .

[14]  M. Bellgard,et al.  A web-based, patient driven registry for Angelman syndrome: the global Angelman syndrome registry , 2017, Orphanet Journal of Rare Diseases.

[15]  G. Watts,et al.  A Web-Based Registry for Familial Hypercholesterolaemia. , 2017, Heart, lung & circulation.

[16]  J. Nikles,et al.  A series of N-of-1 trials to assess the therapeutic interchangeability of two enalapril formulations in the treatment of hypertension in Addis Ababa, Ethiopia: study protocol for a randomized controlled trial , 2017, Trials.

[17]  Lee Render,et al.  A Registry Framework Enabling Patient-Centred Care. , 2015, Studies in health technology and informatics.

[18]  Erik Schultes,et al.  The FAIR Guiding Principles for scientific data management and stewardship , 2016, Scientific Data.

[19]  S. Berry,et al.  Efficiencies of platform clinical trials: A vision of the future , 2016, Clinical trials.

[20]  J. McNeil,et al.  Rare disease registries: a call to action , 2017, Internal medicine journal.

[21]  Adam Hunter,et al.  A modular approach to disease registry design: Successful adoption of an internet‐based rare disease registry , 2012, Human mutation.

[22]  J. Nikles,et al.  The Essential Guide to N-of-1 Trials in Health , 2015, Springer Netherlands.

[23]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[24]  Adam Hunter,et al.  Second generation registry framework , 2014, Source Code for Biology and Medicine.

[25]  J. Connor,et al.  The platform trial: an efficient strategy for evaluating multiple treatments. , 2015, JAMA.

[26]  Martin Frank,et al.  Rare is frequent and frequent is costly: rare diseases as a challenge for health care systems , 2015, The European Journal of Health Economics.

[27]  K. Bushby,et al.  Clinical Outcomes in Duchenne Muscular Dystrophy: A Study of 5345 Patients from the TREAT-NMD DMD Global Database , 2017, Journal of neuromuscular diseases.